Trial intelligence / Profile preview

Pyrotinib plus trastuzumab, docetaxel, and carboplatin for locally advanced HER2-positive breast cancer

ISRCTN72521486Phase 3Active, not recruiting

Sponsor

First Hospital of China Medical University

Start

Oct 2019

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1